MorphoSys Strengthens European Patent Position on anti-CD19

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208

MARTINSRIED / MUNICH, Germany, Dec. 3, 2013 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that the European Patent Office has granted a patent covering the Company's cancer compound MOR208. The new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same. The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "MOR208 will be a key focus area for our development activities in the years to come and thus patent protection in the most relevant markets is of significant importance. Today's patent complements a new US patent covering the MOR208 antibody, which we announced a few weeks ago."

MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies and autoimmune diseases. The antibody has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

MOR208 has shown encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in a Phase 1/2a trial in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study results showed an overall response rate of 29.6% (according to IWCLL 2008 criteria) based on the safety population of the trial (n=27). MorphoSys is conducting Phase 2 clinical trials of MOR208 in patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com

Media Release (PDF) http://hugin.info/130295/R/1747040/588214.pdf

HUG#1747040

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava's Stock Tumble Sparks Investor Class Action

Updated Category News Views 2

A Rocky Day for Endava Investors Here's the thing, on September 21, 2026, Endava plc hit a rough patch that left a mark. After the market closed, the company announced that it had put its Chief Financial Officer, Mark Thurston, on administrative leave. This wasn't just a routine shuffle; it came on the heels of the Board's Audit Committee finding reason to probe into...

Continue Reading
CorePower Yoga Expands in Miami with New Studios

Updated Category News Views 9

Greasing the Wheels of Miami's Wellness Scene If you're living under a rock, you might not have noticed, but CorePower Yoga is making some serious moves in Miami. We're talking about two new studios opening their doors: one in Midtown Miami, already rolling out the mats as of October 19, and another flagship joint soon to hit Coral Gables. Clearly, they see the demand for...

Continue Reading
Geothermal Energy Gets Boost with GRMS Adoption

Updated Category News Views 4

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Continue Reading
Call to Action: Make Disease Cure the Top Election Issue

Updated Category News Views 3

A Call for Congressional Accountability The American Center for Cures is banging the drum for change, and they're banging it loud. Founded by Lou Weisbach, this group has come out swinging, urging Americans to slap disease onto the ballot in the midterms. Why? Because dealing with Alzheimer's, diabetes, heart disease, and cancer every year rips a whopping $1.1 trillion...

Continue Reading
Norwegian Bella™: A New Era in Luxury Cruising

Updated Category News Views 5

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

Continue Reading
NSSF Battles NM's Unconstitutional Gun Law in Court

Updated Category News Views 6

Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...

Continue Reading
Zika Virus: A Surprising Ally in Brain Cancer Fight

Updated Category News Views 9

Here’s something you don’t hear every day: using a virus that typically targets the brain not as a foe, but as a formidable ally in the war against glioblastoma. It’s a gutsy play by UP Oncolytics, a scrappy biotech outfit cradled within Rosalind Franklin University’s Helix 51 incubator. Risky Bet on a Known Adversary Glioblastoma—a real beast in the cancer...

Continue Reading
AI Agents Race: 10M Downloads Spark Competitive Fire

Updated Category News Views 4

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Continue Reading
Parents as Teachers Podcast: Anthem Awards Finalist

Updated Category News Views 4

Celebrating Impact Through Parenthood Narratives Blending heartfelt stories with educational insights, the Parents as Teachers Podcast stands tall as a Finalist in two categories of the 6th Annual Anthem Awards. Recognizing achievements in Content & Media for both Education, Art & Culture and Health, this nod acknowledges the profound impact being made on family...

Continue Reading
PrecisePK Celebrates 40 Years of Revolution in Dosing

Updated Category News Views 1

Forty Years of Changing the Game There’s something to be said for sticking around in an industry for four decades. PrecisePK, a name that's become synonymous with precision dosing, has been revolutionizing how pharmacists do their jobs since 1985. This isn’t just a company resting on its laurels; it’s at the forefront of technological integration in healthcare....

Continue Reading

Top 5 Most Recently Viewed Articles

Transmute and mesur.io Unite to Transform Global Supply Chain Management

Updated Category News Views 373

Transmute and mesur.io Unite for Supply Chain Enhancement In a strategic development set to reshape global trade dynamics, Transmute and mesur.io have combined forces to address the increasing complexities of supply chains. Their primary mission is to mitigate disruptions and risks associated with international commerce. This combination is geared towards fostering a more...

Continue Reading
Transforming $1000 Into $2831 in OR Royalties: A Five-Year Journey

Updated Category News Views 122

Introduction to OR Royalties' Market Performance OR Royalties (NYSE: OR) has made a remarkable impact on investors' portfolios over the last five years. With an impressive annualized return of 23.69%, it has exceeded market expectations by 10.18%, showcasing the company's strong market capitalization of $6.10 billion. Investment Growth Over Five Years If an investor had...

Continue Reading
Drut Technologies Launches Innovative 2500 Series for AI Infrastructure

Updated Category News Views 238

Transforming Data Centers with Drut Technologies' 2500 Series Drut Technologies Inc., a prominent name in photonic data center solutions, is making waves with the introduction of their groundbreaking 2500 product series. This new suite of products is designed to revolutionize data center infrastructure, elevating efficiency, reconfigurability, and performance to...

Continue Reading
SentiLink Hires Kathleen Waid: A Game-Changer for Growth

Updated Category News Views 252

Waid’s Experience Sets the Stage for Growth Here’s the lowdown: SentiLink just snagged Kathleen Waid as their Chief Revenue Officer. That's a solid move, no two ways about it. We're talking about a seasoned pro here, with over 20 years under her belt in scaling fraud prevention and identity verification companies. Now, as the name of the game is increasingly rooted in...

Continue Reading
Pulsecare Medical's NxPFA™ Redefining Atrial Fibrillation Treatment

Updated Category News Views 180

Introducing NxPFA™: A New Era in Atrial Fibrillation Treatment Pulsecare Medical has set itself apart in the realm of cardiovascular intervention with its groundbreaking NxPFA™ system. This revolutionary device is recognized as the world's first nanosecond pulsed field ablation (ns-PFA) system, having achieved marketing approval from China's National Medical Products...

Continue Reading